Overview

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Status:
Completed
Trial end date:
2020-09-02
Target enrollment:
Participant gender:
Summary
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata. Phase 3 Cohort 1: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline. Phase 3 Cohort 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Collaborator:
Sanofi